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Open access under CC BYTAL6003 is an engineered form of human plasmin under development for thrombolytic therapy. TAL6003
(38.2 kDa) contains nine disulﬁde bonds distributed within and between its two functional domains, a
25.2 kDa serine protease domain linked to a 13.0 kDa kringle I domain; kringles 2–5 present in native
human plasmin have been deleted from this plasmin molecule. TAL6003 is expressed as its zymogen
in Escherichia coli and is harvested in inclusion bodies. Following solubilization of inclusion bodies with
urea as the chaotrope and glutathione as the reducing agent, this zymogen is refolded by dilution to a
ﬁnal concentration of 0.5 mg/ml, with a yield of 48% (relative to total zymogen). Refolded TAL6003 zymo-
gen is ﬁltered, diaﬁltered, and ﬁltered again prior to capture and puriﬁcation on SP Sepharose, which is
highly effective in removing host-cell protein. Subsequent afﬁnity puriﬁcation on ECH-Lysine Sepharose
serves to capture polypeptide chains containing correctly refolded kringle 1 domain, which is the locus of
the molecule’s lysine-binding site, and to further eliminate host-cell protein. TAL6003 zymogen eluted
from the ECH-Lysine Sepharose column is activated to TAL6003 with streptokinase, with an activity yield
of approximately 80%. Proteolytically active TAL6003 is stripped of streptokinase by passage through an
anion-exchange (Q) membrane and is then afﬁnity puriﬁed on Benzamidine Sepharose, which serves to
remove unreacted TAL6003 zymogen and proteolytically degraded TAL6003. An ultraﬁltration/diaﬁltra-
tion step, to concentrate and to formulate TAL6003, completes the puriﬁcation process. The ﬁnal product
exhibited a speciﬁc activity of close to unity and high purity by several relevant criteria.
 2012 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
A truncated version of human plasmin (TAL60033) has been
engineered for development as a direct thrombolytic agent [1]. This
recombinant protein retains the two most essential domains of na-
tive plasmin: the serine protease domain (25.2 kDa), which provides
the ﬁbrinolytic capability of plasmin [2]; and the kringle 1 domain
(13.0 kDa), which contains a lysine-binding site that serves to anchor
plasmin to ﬁbrin clots and to facilitate rapid inactivation of non-clot-
bound plasmin by a2-antiplasmin [3,4]. Kringles 2–5 of native
plasmin(ogen) have been deleted from this molecule. TAL6003 is
expressed in Escherichia coli as its inactive zymogen (recombinantimmerman).
of the Philippines Los Banos,
. Box 14627, Research Triangle
ic acid; SDS–PAGE, sodium
SK, streptokinase; TAL6003,
s 2-5 of native plasmin(ogen)
human plasminogen deletion
-NC-ND license. plasminogen); the refolded zymogen molecule contains nine disul-
ﬁde bonds and is activated to TAL6003 with streptokinase (SK). This
paper describes the production and puriﬁcation of TAL6003 by a pro-
cess that is scalable for commercial manufacturing.Materials and methods
Expression of TAL6003
The amino acid sequence of TAL6003 zymogen differs slightly
from that described recently for the similar plasminogen deletion
mutant D(K2-K5)Pg [1] and is shown in Fig. 1. The primary struc-
ture of TAL6003 zymogen begins at Met69 [instead of at Met19, as in
D(K2-K5)Pg] and has the linker sequence VPQ in place of ILE at
positions 160–162 (human plasminogen numbering system); the
latter change was incorporated to make the linker region joining
the kringle to the serine protease domain identical to that of the
native kringle 5-serine protease sequence. These two different
N-terminal sequences of D(K2-K5)Pg and TAL6003 zymogen both
yield identical N-termini of Lys78 and Val79 after activation by SK
and cleavage of the pre-activation peptide. Thus, after activation
by SK, D(K2-K5)Pm and TAL6003 differ only in the 3-amino acid
segment in the linker region. Construction of the expression vector
Fig. 1. Amino acid sequence of recombinant plasminogen (TAL6003 zymogen). The shaded segments denote the protein sequences that were combined to produce TAL6003
zymogen. The singly-underlined sequence represents kringle 1, while the doubly-underlined sequence represents the serine protease domain. The arrow designates the
arginine-valine activation site whose cleavage converts single-chain TAL6003 zymogen into two-chain recombinant plasmin (TAL6003).
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scribed for D(K2-K5)Pg [1]. The mean yield of inclusion bodies iso-
lated from 100 L of culture was 2.17 ± 0.63 kg (n = 3), which
contained approximately 20% TAL6003 zymogen protein by
weight. Based upon SDS–PAGE analysis, the major portion of ex-
pressed protein was present in the insoluble inclusion body mate-
rial from lysed cells (results not shown).
Refolding of TAL6003 zymogen
Crushed, frozen inclusion bodies (26 g, derived from approxi-
mately 260 g of wet cell paste) were added to 480 ml of cold solu-
bilization buffer (7 M urea, 10 mM reduced glutathione, 10 mM
Tris, 0.25 M arginine, 2.0 mM EDTA, pH 7.5), and this suspension
was stirred vigorously at 6 C for 4 h. This solution of solubilized
inclusion bodies was then added slowly, over approximately 1 h,
into 19 volumes of cold refolding buffer [0.5 M urea, 1.0 mM each
of reduced and oxidized glutathione, 0.5 M arginine, 1.0 mM EDTA,
5.0 mM e-ACA, 50 mM Tris, pH 8.0] and stirred for 17 h in the cold.
The TAL6003 zymogen concentration in this refolding milieu was
approximately 0.5 mg/ml. e-ACA, a lysine analog, is added here
and in other process steps to prevent TAL6003 (zymogen) from
associating either with itself or with other proteins via the ly-
sine-binding site present on the kringle domain.
Filtration/diaﬁltration of TAL6003 zymogen
The refolding mixture was clariﬁed by passing it initially
through a 0.054 m2 Millipore Millistak Pod + A1HC depth ﬁlter.
This ﬁltrate was further ﬁltered through a 0.01 m2 Millipore Ex-
press SHC Opticap XL 150 ﬁlter (0.5/0.2 lm). Diaﬁltration of this
latter ﬁltrate was performed with two 0.11 m2 30 kDa GE Health-care Kvick cassettes. The diaﬁltration buffer was 10 mM Tris,
1.0 mM EDTA, 5.0 mM e-ACA, 50 mM urea, pH 9.0. Between 37
and 40 L of buffer exchange was required to reach the target con-
ductivity of 1–2 mS/cm. The higher pH (9.0) was used to improve
protein solubility and ﬁltration behavior.SP sepharose pre-ﬁltration
To prevent fouling of the SP Sepharose column, the above diaﬁl-
tration retentate was routinely passed through a 1.0/0.2 lm Milli-
pore Polysep II Opticap XL2 ﬁlter.SP sepharose chromatography of TAL6003 zymogen
Refolded TAL6003 zymogen was captured on a 206-ml column
of SP Sepharose FF (GE Healthcare) at room temperature. The col-
umn equilibration buffer was 25 mM Tris, 1.0 mM EDTA, pH 8.0.
After the column was washed with 10 column volumes of equili-
bration buffer, TAL6003 zymogen was eluted with 25 mM Tris,
200 mM NaCl, 1.0 mM EDTA, pH 8.0.ECH-Lysine sepharose chromatography of TAL6003 zymogen
The eluate from the SP Sepharose column was loaded at room
temperature onto a 295-ml column of ECH-Lysine Sepharose 4 FF
(GE Healthcare) equilibrated with 50 mM Tris, 200 mM NaCl,
1.0 mM EDTA, pH 8.0. After the column was washed with 4 column
volumes of equilibration buffer, TAL6003 zymogen was eluted with
50 mM Tris, 20 mM e-ACA, 1.0 mM EDTA, pH 8.0. This column elu-
ate was stored frozen at 80 C until the next step in the puriﬁca-
tion process was initiated.
Fig. 2. SDS–PAGE (reduced) analysis of TAL6003 puriﬁcation intermediates. Sam-
ples were run on a 4–12% polyacrylamide gel, under reducing conditions, and
stained with Coomassie Blue R-350 dye. Gel lanes 2–9 were each loaded with 3.5 lg
of total protein. Lanes 1 and 10, molecular weight markers; lane 2, solubilized
inclusion bodies; lane 3, refolded TAL6003 zymogen; lane 4, SP Sepharose eluate;
lane 5, ECH-Lysine Sepharose eluate; lane 6, SK-activated TAL6003; lane 7,
Benzamidine Sepharose load; lane 8, Benzamidine Sepharose eluate; lane 9, ﬁnal
formulation TAL6003. Arrows to the right of the gel indicate autolysis products of
TAL6003.
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Thawed TAL6003 zymogenwas activatedwith SK for 4 h at room
temperature under the following solution conditions: 2.5 mg of
TAL6003 zymogen/ml; 12.5% (v/v) 1,2-propanediol; 200 mM
e-ACA; 87.5% (v/v) ECH-Lysine Sepharose elution buffer; 25 lg of
SK/ml; pH 7.0. 1,2-Propanediol was used as a less-viscous substi-
tute for glycerol [5] to reduce autolysis of activated TAL6003.
Q membrane removal of SK
The SK-activation mixture was diluted 1:1 with 200 mM e-ACA/
12.5% 1,2-propanediol and pH adjusted to 9.0. This solution was
passed through a Sartobind SingleSep Q Nano 1-ml membrane
(Sartorius) at room temperature.
Benzamidine sepharose chromatography of TAL6003
The Q membrane ﬂow-through was supplemented with NaCl
(to 0.5 M) and pH adjusted to 7.0 prior to being loaded onto a
200-ml column of Benzamidine Sepharose 4 FF (high sub) (GE
Healthcare) equilibrated with 25 mM Tris, 500 mM NaCl, 250 mM
e-ACA, pH 7.0 at room temperature. After the column was washed
with 5 column volumes of equilibration buffer, TAL6003 was
eluted with 300 mM sodium citrate, 200 mM e-ACA, 300 mM NaCl,
pH 3.0. This column eluate was collected in a vessel containing one
column volume of elution buffer, for the purpose of lowering the
pH (to 3.0) of TAL6003 present in the peak front.
Ultraﬁltration/diaﬁltration of TAL6003
TAL6003 present in the eluate from the Benzamidine Sepharose
column was concentrated approximately 5-fold (to 5 mg/ml) and
diaﬁltered against 5.0 mM sodium citrate (pH 3.3), using a 5 kDa
Millipore Pellicon XL (0.005 m2) membrane. Following diaﬁltra-
tion, this acidic TAL6003 solution was stored at 80 C.
Determination of protein concentration, activity and purity
Total protein was quantiﬁed by the pyrogallol red method [6];
because this assay exhibits differential responses with various pro-
teins, a TAL6003 zymogen standard was used that had been cali-
brated based upon its absorbance at 280 nm. The extinction
coefﬁcient for pure TAL6003 at 280 nm was calculated to be
1.66 mg1 ml, based upon amino acid composition. TAL6003 zymo-
gen activity was assayed using the COAMATIC Plasminogen kit
(DiaPharma Group, Inc.). The latter kit was also used to assay
TAL6003 activity but without addition of SK to the assay mixtures;
these assays were calibrated and validated to measure the concen-
tration of catalytically-active TAL6003 (zymogen). Conventional
SDS–PAGE was performed under reducing conditions [7]; protein
bands were stained with Coomassie Blue (SimplyBlue™ SafeStain,
Invitrogen Life Technologies). Size-exclusion HPLC was performed
with a 7.8 mm  30 cm TSK-GEL G2000SWXL column (Tosoh Bio-
Science) with 10 mM acetic acid, 100 mM NaCl, pH 3.4, as mobile
phase. E. coli BL21 host-cell proteins were assayed with an ELISA
kit from Cygnus Technologies. SK was estimated with a semi-
quantitative Western blot using custom-prepared, afﬁnity-puriﬁed
rabbit anti-SK sera.
Results
Puriﬁcation of TAL6003 zymogen
The puriﬁcation of TAL6003 is divided conceptually and
experimentally into two distinct processes: refolding of TAL6003zymogen from solubilized inclusion bodies, followed by puriﬁca-
tion to homogeneity of correctly refolded TAL6003 zymogen; and
activation of puriﬁed TAL6003 zymogen by SK, followed by puriﬁ-
cation and formulation of TAL6003. Accordingly, Tables 1 and 2
summarize puriﬁcation data for TAL6003 zymogen and TAL6003,
respectively, from three separate lots of inclusion bodies. Each of
these three puriﬁcation procedures was started with approxi-
mately 4–5 g of total protein present in inclusion bodies.
Solubilized inclusion bodies were analyzed by reducing SDS–
PAGE; based upon densitometric analysis of Coomassie Blue-
stained gels, approximately 70% of the total protein was estimated
to be TAL6003 zymogen (Fig. 2, Lane 2). Thus, deposit of expressed
TAL6003 zymogen in inclusion bodies provided relatively pure tar-
get protein at the beginning of this process.
Solubilized/reduced TAL6003 zymogen from inclusion bodies
was oxidatively refolded, by dilution refolding, to catalytically-ac-
tive protein (determined in the presence of stoichiometric SK) hav-
ing a speciﬁc activity of 0.34; this corresponds to an estimated
yield of 34% for the refolding step (relative to total protein). If
the refolding yield is normalized based only upon the content of
TAL6003 zymogen protein present in inclusion bodies, it increases
to approximately 48%.
Chromatography of refolding mixtures containing TAL6003
zymogen on SP Sepharose requires prior elimination of arginine.
Accordingly, refolding mixtures were ﬁrst passed through a depth
ﬁlter, to remove particulate aggregates of protein, and were then
diaﬁltered against 10 mM Tris, 1.0 mM EDTA, 5.0 mM e-ACA,
50 mM urea, pH 9.0. A subsequent ﬁltration prior to chromatogra-
phy was done to safeguard against fouling of the SP Sepharose col-
umn. Recovery of TAL6003 zymogen activity through these three
sequential ﬁltration/diaﬁltration/ﬁltration steps was approxi-
mately 79%. The SP Sepharose column eluate provided nearly
homogeneous TAL6003 zymogen, having a speciﬁc activity of
0.99, with a recovery of approximately 92% of the TAL6003 zymo-
gen activity. This chromatography was highly effective in reducing
contamination of TAL6003 zymogen by host-cell protein (Table 1).
TAL6003 zymogen eluted from the SP Sepharose column was
subsequently bound to, and eluted from, an ECH-Lysine Sepharose
column. This latter afﬁnity chromatography step serves to conﬁrm
that all of the protein processed further downstream contains a
correctly refolded lysine-binding site on the kringle domain. Nearly
complete recovery of TAL6003 zymogen was achieved from the
44 R. Aguda et al. / Protein Expression and Puriﬁcation 88 (2013) 41–46ECH-Lysine Sepharose chromatography step, with a speciﬁc activ-
ity of unity. This column was also effective in further reducing the
content of host-cell protein. ECH-Lysine Sepharose eluates were
routinely stored frozen at 80 C as a stable storage form of
TAL6003 zymogen prior to activation.
Activation of TAL6003 zymogen and puriﬁcation of TAL6003
SK was used to activate TAL6003 zymogen to TAL6003 in free
solution. The conditions for activation were selected carefully to
maximize activation of TAL6003 zymogen and to minimize autol-
ysis. The speciﬁc activity of TAL6003 at the end of the 4-h activa-
tion period was 0.76, indicating an approximately 80% yield at
this step.
SK-activated TAL6003 was then passed through a Q membrane
to remove SK, with 87% recovery of TAL6003; this separation is
made possible by the disparate pI values for TAL6003 (9.3 and
9.5, results not shown) and SK (5.2) [8]. Based upon Western blot
analysis of the load material and ﬂow-through from this Q mem-
brane, SK was reduced to below the level of quantiﬁcation by this
step. The Q membrane ﬂow-through was loaded onto a Benzami-
dine Sepharose column to bind active TAL6003 and to eliminate
unreacted TAL6003 zymogen and autolyzed TAL6003. TAL6003
activity was recovered with a yield of approximately 96% during
this step. The Benzamidine Sepharose eluate was then concen-
trated by ultraﬁltration and diaﬁltered to transfer the protein into
its desired formulation buffer (5.0 mM sodium citrate, pH 3.3). This
low-pH formulation of TAL6003 is stored in stable form frozen at
80 C. Processing and formulation of TAL6003 at low pH is based
upon the reversible inhibitory effect of low pH on the activity of
serine proteases [9], such as plasmin.
Purity of TAL6003
The primary criterion for purity of TAL6003 zymogen and
TAL6003 is the speciﬁc activity of the preparations, with a speciﬁc
activity of 1.0 representing 100% pure, active protein. As shown in
Tables 1 and 2, the speciﬁc activities of the TAL6003 zymogen
intermediate and the TAL6003 ﬁnal product were both close to
unity. Corroborating these estimations of purity are the SDS–PAGE
results presented in Fig. 2, which illustrate the progressive puriﬁ-
cation of TAL6003 zymogen, conversion of single-chain TAL6003
zymogen into two-chain TAL6003 by SK, and puriﬁcation of
TAL6003. A small percentage of autolysis products was observed
in the ultraﬁltered/diaﬁltered TAL6003 at the end of them
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Fig. 3. Size-exclusion analysis of puriﬁed TAL6003. Elution proﬁles (A280) for the three
constituted 98.3 ± 0.1% of the absorbance eluted from the column during each run. Thepuriﬁcation process (Fig. 2, lane 9). Size-exclusion HPLC analyses
of the three samples of ﬁnal product are overlaid in Fig. 3; this
analysis demonstrated that 98% of the protein was eluted in the
peak corresponding to monomeric TAL6003. Host-cell protein
was reduced to <0.9 ng/mg of puriﬁed TAL6003. SK was reduced
to below the level of quantiﬁcation (<0.02 lg/mg of TAL6003).
Yield of TAL6003
TAL6003 zymogen protein present in solubilized inclusion
bodies was refolded into active protein with a yield of approxi-
mately 48% (based upon inclusion bodies containing 70%
TAL6003 zymogen). The overall recovery of TAL6003 zymogen
activity after ECH-Lysine Sepharose chromatography, based upon
active, refolded TAL6003 zymogen, was 69%. The yield of
TAL6003 activity, based upon starting TAL6003 zymogen activity,
was 70%. Thus, the calculated overall yield of TAL6003, relative
to active, refolded TAL6003 zymogen, was 48% for the three puriﬁ-
cation runs presented in Tables 1 and 2.
Discussion
The objective of this work was to devise a puriﬁcation process
for recombinant plasmin (TAL6003) that maximized TAL6003 pur-
ity and yield and that was scalable for manufacturing. Given that
this protein molecule contains nine disulﬁde bonds and had to
be processed part way as a fully active protease, this undertaking
was viewed from the outset to be a technical challenge. Neverthe-
less, in its important aspects, this objective has been met.
The fundamental strategy of this puriﬁcation scheme was to
produce TAL6003 as its inactive zymogen in E. coli inclusion bodies,
which contained approximately 70% TAL6003 zymogen with re-
spect to total protein and which, therefore, represented a signiﬁ-
cant puriﬁcation step in itself. Oxidative refolding conditions for
solubilized inclusion bodies afforded approximately 48% recovery
of TAL6003 zymogen in its biologically active form. Refolded
TAL6003 zymogen is then captured and puriﬁed to a high extent
on an SP Sepharose column. Subsequent afﬁnity puriﬁcation of
TAL6003 zymogen on ECH-Lysine Sepharose serves to verify that
all molecules processed further contain a correctly refolded kringle
domain, the locus of the lysine-binding site and a critical feature
for the intended therapeutic use of TAL6003.
The second half of the puriﬁcation process was initiated by acti-
vation of recombinant plasminogen (TAL6003 zymogen) to proteo-
lytically-competent, recombinant plasmin (TAL6003) with SK. ThisMonomer
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preparations of puriﬁed TAL6003 are overlaid in this ﬁgure. Monomeric TAL6003
remainder (1.7 ± 0.1%) of the eluted absorbance was eluted before the main peak.
Table 1
Puriﬁcation of recombinant plasminogen (TAL6003 zymogen) from E. coli inclusion bodies.
Puriﬁcation step Protein concentration
(mg/ml)
Total protein
(mg)a,b
Total activity
(mg)a,b
Cumulative
activity yield (%)a,b
Speciﬁc
activityc
Host-cell protein
(ng/mg protein)
Solubilized inclusion bodies (26 g) 8.88 ± 0.72 4,491 ± 366 —d –d –d DNDf
Refolded TAL6003 zymogen 0.51 ± 0.05 5,205 ± 522 1,743 ± 66 33.6 ± 2.2 0.34 ± 0.02 DND
(Post-refold ﬁltrate TAL6003 zymogen) 0.38 ± 0.02 4,354 ± 285 1,730 ± 203 99.1 ± 8.5e 0.40 ± 0.02 DND
(Diaﬁltration retentate TAL6003 zymogen) 0.36 ± 0.01 3,411 ± 140 1,542 ± 250 88.2 ± 11.2e 0.49 ± 0.01 DND
(Pre-SP Sepharose ﬁltrate TAL6003 zymogen) 0.33 ± 0.01 3,313 ± 186 1,379 ± 5 79.2 ± 3.1e 0.42 ± 0.03 2464 ± 897
SP Sepharose eluate TAL6003 zymogen 2.31 ± 0.16 1,282 ± 47 1,270 ± 35 73.0 ± 4.7e 0.99 ± 0.06 31.9 ± 20.5
ECH Lysine eluate TAL6003 zymogen 6.20 ± 0.16 1,184 ± 31 1,195 ± 34 68.7 ± 4.6e 1.01 ± 0.01 1.6 ± 1.4
a Values represent the mean ± the standard deviation from the mean for three different puriﬁcation runs, each starting with a different batch of inclusion bodies.
b Values not corrected for volume of sample withdrawn for bioanalytical assays.
c Speciﬁc activity, mg of active TAL6003 (following activation of zymogen by streptokinase) per mg of total protein.
d Did not do activity analysis on these samples, because the protein was completely denatured.
e These cumulative yields were calculated relative to the amount of refolded TAL6003 zymogen achieved.
f Did not analyze these samples for host-cell protein.
Table 2
Puriﬁcation of recombinant plasmin (TAL6003) from puriﬁed TAL6003 zymogen.
Puriﬁcation step Protein
concentration
(mg/ml)
Total
protein
(mg)a,b
Total activity
(mg)a,b
Cumulative activity
yield (%)a,b
Speciﬁc
activityc
Host-cell protein
(ng/mg protein)
SK (lg/mg
protein)
Pre-activation TAL6003 zymogen 2.43 ± 0.04 626 ± 57 589 ± 38 (100) 0.94 ± 0.03 DNDd DND
Streptokinase-activated TAL6003 2.49 ± 0.02 641 ± 52 488 ± 47 82.8 ± 3.5 0.76 ± 0.03 DND 4.2 ± 1.5
Q membrane ﬂow-through 0.99 ± 0.01 567 ± 41 425 ± 30 72.2 ± 0.6 0.75 ± 0.01 DND <QLe
Benzamidine Sepharose eluate TAL6003 0.89 ± 0.06 384 ± 32 408 ± 39 69.1 ± 3.1 1.06 ± 0.06 <12 <QL
Ultraﬁltered/diaﬁltered TAL6003 5.86 ± 0.13 435 ± 22 414 ± 11 70.5 ± 3.2 0.95 ± 0.03 <0.9 <QL
a Values not corrected for volume of sample withdrawn for bioanalytical assays.
b Values represent the mean ± the standard deviation from the mean for three different puriﬁcation runs, each starting with a different batch of ECH Lysine eluate TAL6003
zymogen.
c Speciﬁc activity, mg of active TAL6003 per mg of total protein.
d Did not perform analysis on these samples.
e Below the level of quantiﬁcation (0.15 lg/ml).
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zymogen to TAL6003 while minimizing autolysis of TAL6003 dur-
ing the activation period (4 h). Under the conditions devised,
approximately 80% yield of active TAL6003 was achieved. The acti-
vated TAL6003 is then stripped of SK by passage through a Q mem-
brane followed by afﬁnity chromatography on Benzamidine
Sepharose, which serves to remove autolyzed TAL6003 and unacti-
vated TAL6003 zymogen. An ultraﬁltration/diaﬁltration step then
serves to concentrate the ﬁnal product and to transfer it into its
formulation buffer (5.0 mM sodium citrate, pH 3.3).
TAL6003 produced at the lab scale by this process demonstrates
reproducible purity of P90%, as assessed by speciﬁc activity and
size-exclusion HPLC and as corroborated by reduced SDS–PAGE
(Fig. 2, lane 9), which demonstrated the presence of less than
10% autolysis products. Host-cell (E. coli) protein was reduced to
<0.9 ng/mg of TAL6003. SK levels were below quantiﬁable level
(<0.02 lg/mg of TAL6003) in the ﬁnal product.
The overall yield of TAL6003 was limited by several different
steps in this puriﬁcation scheme. TAL6003 zymogen protein was
refolded to the extent of approximately 48% from the solubilized
inclusion bodies. Approximately 20% of the refolded TAL6003
zymogen was lost during ﬁltration of the refolding mixture, subse-
quent ultraﬁltration/diaﬁltration, and a pre-column ﬁltration of
this latter retentate. TAL6003 zymogen was converted to proteo-
lytically-competent TAL6003 by SK to the extent of approximately
83%, the difference representing unreacted TAL6003 zymogen and
autolyzed TAL6003. All three of the column chromatography steps
gave product recoveries of >90%. The cumulative recovery of
TAL6003 zymogen activity after the ECH-Lysine Sepharose column,
based upon successfully refolded protein, was 69%. The cumulative
recovery of TAL6003 activity from TAL6003 zymogen activity was70%. Thus, the net yield of TAL6003 from refolded TAL6003 zymo-
gen over this entire puriﬁcation process was approximately 48%.
Each step in this TAL6003 puriﬁcation process was designed
to be scalable for manufacture of this recombinant protein.
The lab-scale experiments described above each started with
approximately 5 g of inclusion body protein. Each of the three
SK-activation reactions was started with 625 mg of protein.
Puriﬁcation of TAL6003 from inclusion bodies has been carried
out successfully at pilot-plant scale without decrease in TAL6003
purity or yield and without complication.
In summary, conditions have been identiﬁed that provide a high
yield (48%) of oxidative refolding of denatured/reduced TAL6003
zymogen, whose biologically-active structure contains nine disul-
ﬁde bonds. Once converted into its proteolytically active form by
SK, TAL6003 was puriﬁed to a speciﬁc activity close to unity and
with high yield, as a stable formulation in weakly acidic medium
(5.0 mM sodium citrate, pH 3.3). As reported separately [1,10],
TAL6003 effectively binds to eACA and ﬁbrin, is rapidly inhibited
by a2-antiplasmin, and exhibits good hemostatic safety in
rabbits. TAL6003 prepared by the above-described process was
shown to be highly effective in clot lysis, both in vitro and
in vivo, and to exhibit a good safety proﬁle in rats [11]. The keys
to success in processing this active protease were the use of eACA,
1,2-propanediol, and low pH, in different process steps, to prevent
autolysis.
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